PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference 2025 taking place on Friday, February 28, 2025.

Read more at globenewswire.com